Evidence map›Paper›PMID 42147610›Full record

ArticleCureus2026

Recognizing the Physiologic Signature of Oncologic Emergency: A Case of Burkitt Lymphoma Presenting With Early Laboratory Indicators of High Tumor Burden.

Alireza Izadian Bidgoli, Alberto Gomez Veliz

Abstract readCase Reports
In one paragraph

Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Alireza Izadian BidgoliInternal Medicine, American University of the Caribbean School of Medicine, Cupecoy, SXM.
Alberto Gomez VelizInternal Medicine, Jackson Memorial Hospital, Miami, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Burkitt lymphoma is a highly aggressive B-cell malignancy characterized by rapid proliferation and a narrow therapeutic window in which early recognition of disease progression is critical to prevent morbidity. While diagnosis is typically established through histopathology and imaging, evolving physiologic and radiographic changes may provide early indicators of aggressive disease behavior, particularly in the post treatment setting. We present a 26-year-old male patient with previously treated Epstein-Barr virus-positive Burkitt lymphoma who presented with acute lower back pain, urinary symptoms, and rapid clinical deterioration consistent with disease progression. Laboratory evaluation demonstrated normocytic anemia, markedly elevated lactate dehydrogenase, progressive leukocytosis, and hypoalbuminemia, consistent with a high tumor burden. Cross-sectional imaging revealed interval enlargement of a necrotic pelvic mass with associated hydronephrosis, while MRI demonstrated diffuse marrow infiltration. Fluorodeoxyglucose-Positron emission tomography/Computed tomography (FDG PET/CT) showed extensive hypermetabolic disease involving nodal and extranodal sites, consistent with systemic progression. Peripheral blood flow cytometry failed to identify a clonal B-cell population, a finding consistent with known limitations of circulating markers in Burkitt lymphoma, particularly following recent chemotherapy. This case highlights a physiologic pattern of oncologic emergency, defined by integrated laboratory abnormalities, imaging progression, and clinical decline as indicators of disease progression. Recognition of these features may facilitate timely therapeutic escalation despite inconclusive peripheral findings.

Indexed as

burkitt lymphomadiagnostic delaylactate dehydrogenaseoncologic emergencytumor burden

Identifiers

PMID42147610
PMCPMC13179846

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.